© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
According to a study, Egrifta can improve fatty liver disease in people with HIV.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
